Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ARVN
HoldFallen FavouriteArvinas, Inc. · Healthcare · United States · $592M · Avg Vol: $7M/d
COMPANY DESCRIPTION
Arvinas, Inc. is a clinical-stage biopharmaceutical company pioneering the development of novel therapies through its proprietary PROTAC® protein degradation technology. The company holds a leading position in this innovative therapeutic modality, which aims to selectively degrade disease-causing proteins, opening new avenues for treating intractable diseases. Its advanced platform and strategic collaborations with major pharmaceutical companies underpin its competitive advantage in a high-potential, disruptive biotechnology space.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 131.4M | 78.5M | 263.4M | 262.6M | 26.0% | 316.7M | 296.1M | 12.8% |
| EPS | -3.82 | -5.31 | -6.62 | -2.77 | -1.14 | — | 0.26 | -2.85 | — |
| Shares | — | 53.2M | 68.0M | 68.8M | 63.5M | +19.4% | 64.5M | — | — |
| Debt | — | 5.5M | 3.2M | 9.7M | 8.9M | 17.4% | 8.0M | — | — |
| Equity | — | 564.9M | 660.0M | 561.6M | 433.8M | -8.4% | — | — | — |
| Op CF | — | -273.5M | -347.8M | -259.3M | -273.8M | — | -207.0M | — | — |
| Inv CF | — | 242.8M | 203.5M | 34.7M | 407.6M | — | — | — | — |
| Fin CF | — | 4.7M | 374.7M | 7.9M | -91.4M | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ARVN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ARVN | Arvinas, Inc.(you) | $592M | 40 | Hold |
| OABI | OmniAb, Inc. | $650M | 40 | Hold |
| ARTV | Artiva Biotherapeutics, Inc. | $542M | 37 | Hold |
| OVID | Ovid Therapeutics Inc. | $547M | 35 | Sell |
| CLYM | Climb Bio, Inc. | $837M | 40 | Hold |
| GYRE | Gyre Therapeutics, Inc. | $699M | 34 | Sell |
| SGMT | Sagimet Biosciences Inc. | $656M | 32 | Sell |
| NGNE | Neurogene Inc. | $732M | 34 | Sell |
| CTNM | Contineum Therapeutics, Inc. | $641M | 30 | Sell |
| MNPR | Monopar Therapeutics Inc. | $751M | 47 | Hold |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%